Reports Q4 revenue $0.3M, consensus $1.03M. “In 2023, Absci further solidified its leadership in AI-driven biologic drug discovery,” said Sean McClain, Founder and CEO. “Our breakthroughs in generative AI drug creation have rapidly translated into a differentiated internal portfolio of potential best-in-class and first-in-class programs. With validating strategic industry partnerships and our recent underwritten public offering, we’re poised to further advance our pipeline, enhance our AI capabilities, and expand our partnerships. These efforts reflect our commitment to innovation, promising better biologics for patients, faster.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABSI:
- Absci Corp. (ABSI) Q4 Earnings Cheat Sheet
- Absci initiated with an Outperform at Scotiabank
- Absci cash raise removes key share overhang, says Truist
- Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Cathie Wood’s ARK Investment bought 2.99M shares of Absci today
